Standard Biotools Inc
$ 0.89
-2.12%
12 Jun - close price
- Market Cap 347,502,000 USD
- Current Price $ 0.89
- High / Low $ 0.93 / 0.88
- Stock P/E N/A
- Book Value 1.44
- EPS -0.13
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.10 %
- 52 Week High 1.72
- 52 Week Low 0.79
About
Standard Biotools Inc. (LAB) is a leading biotechnology firm focused on advancing genomic analysis and biological research through innovative tools and technologies. The company specializes in the development of high-performance products tailored for laboratories within genomics and proteomics, delivering enhancements in research precision and efficiency. Leveraging proprietary platforms, Standard Biotools accelerates scientific discoveries, positioning itself at the forefront of the rapidly evolving biotechnology sector. With a commitment to addressing the increasing demand for advanced analytical solutions, LAB is well-positioned to support advancements in the life sciences industry.
Analyst Target Price
$1.55
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-18 | 2025-11-04 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.02 | 0.0672 | -0.04 | -0.05 | -0.07 | -0.0494 | -0.03 | -0.08 | -0.24 | -0.25 | -0.14 | -0.14 |
| Estimated EPS | -0.02 | -0.0533 | -0.02 | -0.09 | -0.07 | -0.03 | -0.07 | -0.07 | -0.1 | -0.13 | -0.12 | -0.1 |
| Surprise | 0 | 0.1205 | -0.02 | 0.04 | 0 | -0.0194 | 0.04 | -0.01 | -0.14 | -0.12 | -0.02 | -0.04 |
| Surprise Percentage | 0% | 226.0788% | -100% | 44.4444% | 0% | -64.6667% | 57.1429% | -14.2857% | -140% | -92.3077% | -16.6667% | -40% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.01 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LAB
2026-06-09 21:39:29
This SCHEDULE 13D/A filing reports an amended major shareholder report for Standard BioTools Inc. (LAB) by Casdin Capital, LLC and affiliated entities. The filing details their beneficial ownership percentages and outlines a recent merger agreement between Standard BioTools Inc. and Treeline Biosciences, Inc., for which the Casdin entities have entered into a voting and lock-up agreement.
2026-06-08 17:10:34
Fenwick is representing Treeline Biosciences in its definitive merger agreement with Standard BioTools Inc. The combined company will operate as Treeline Biosciences, focusing on advancing its pipeline of small molecule inhibitors, protein degraders, and antibody-drug conjugates. This transaction is expected to add approximately $450 million in net cash from Standard BioTools, resulting in over $900 million in pro-forma cash for the combined entity, sufficient to fund operations into 2029.
2026-06-08 15:08:49
Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. have announced an all-stock merger to form a new public biopharma company, Treeline Biosciences (TRLN), focused on oncology and precision medicines. The combined entity is expected to have over $900 million in pro-forma cash, providing an operational runway into 2029, and will be led by Dr. Josh Bilenker, co-founder and CEO of Treeline. Standard BioTools shareholders will receive contingent value rights for potential future payouts from legacy asset monetization and earnouts from the SomaLogic business sale, with the merger anticipated to close in the second half of 2026.
2026-06-08 12:08:49
Standard BioTools (LAB) has agreed to an all-stock merger with Treeline Biosciences, valuing Treeline at $2.5 billion and Standard BioTools at $460 million, adjusted for net cash. Post-merger, former Treeline holders will own approximately 84% of the combined entity, which will be renamed Treeline Biosciences Holdings. The deal also includes voting commitments from major holders, lock-up agreements for insiders, and a five-year Contingent Value Rights (CVR) agreement to distribute proceeds from legacy asset monetization to existing Standard BioTools stockholders.
2026-06-08 12:08:49
Standard BioTools Inc. (NASDAQ: LAB) is merging with Treeline Biosciences in an all-stock transaction, transforming Standard BioTools into a clinical-stage biotechnology company focused on precision medicines for cancer and other serious diseases. The combined entity, which will operate as Treeline Biosciences (TRLN) and trade on Nasdaq, is expected to launch with over $900 million in pro forma cash, funding operations into 2029. Treeline Biosciences, founded in 2021, has rapidly advanced several oncology programs into clinical development, including lead candidates targeting BCL6, pan-KRAS, and EZH2, with leadership largely remaining with Treeline's experienced team.
2026-06-08 11:08:49
Standard BioTools Inc. and Treeline Biosciences, Inc. have announced a definitive merger agreement in an all-stock transaction. The combined company, to be named Treeline Biosciences, will focus on advancing a pipeline of small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates, with over $900 million in cash expected at closing. Treeline's CEO, Josh Bilenker, MD, will lead the new entity, which anticipates clinical data readouts starting in 2027 and plans for additional programs to enter the clinic in oncology, neurology, and immunology.
